• DOT1L Inhibition Mitigates Renal Fibrosis via Epigenetic Mod

  2026-06-02

  This study demonstrates that selective inhibition of DOT1L, specifically using EPZ5676, can attenuate renal fibrosis by suppressing renal fibroblast activation and epithelial-mesenchymal transition (EMT). The findings underscore a novel epigenetic mechanism with implications for chronic kidney disease research and potential therapeutic targeting.

• Nose-to-Brain Rotigotine Nanoparticles for Parkinson’s Model

  2026-06-02

  This study demonstrates that chitosan nanoparticle-based nose-to-brain delivery of Rotigotine hydrochloride enhances neuronal uptake, neuroprotection, and behavioral recovery in Parkinson’s disease models. The findings highlight a significant advance in overcoming bioavailability barriers for dopaminergic therapies and provide groundwork for translational research in antiparkinsonian strategies.

• Cy5 NHS ester(Et): Technical Guidance for Protein Labeling

  2026-06-01

  Cy5 NHS ester(Et) is designed for covalent, water-soluble fluorescent labeling of primary amines in proteins, peptides, and related biomolecules, supporting applications such as immunofluorescence staining, flow cytometry, and fluorescence microscopy. It is not suitable for ethanol-based workflows or for protocols that require long-term storage of working solutions. Immediate-use labeling with proper solubilization and storage is essential for consistent results.

• Super-Enhancer Hijacking of LINC01977 in Early LUAD Progress

  2026-06-01

  Zhang et al. uncover how super-enhancer-driven activation of LINC01977 lncRNA drives malignancy in early-stage lung adenocarcinoma via the canonical TGF-β/SMAD3 axis. Their integrative epigenetic approach highlights new therapeutic targets and experimental models for transcriptional coactivator inhibition in lung cancer research.

• Foretinib (GSK1363089): Advancing Quantitative Cancer Drug R

  2026-05-31

  Explore how Foretinib (GSK1363089) enables nuanced, quantitative evaluation of tumor cell growth inhibition and cell death in modern cancer research. This article uniquely integrates in vitro assay advances and protocol optimization for translational impact.

• 8-Chloroadenosine: Precision Nucleoside Analog in RNA Resear

  2026-05-30

  8-Chloroadenosine offers researchers unmatched precision in dissecting RNA metabolism and transcriptional regulation, especially in cancer models. Its high purity and robust inhibition profile make it an essential molecular biology reagent for advanced workflows.

• Strategic Inhibition of Non-Muscle Myosin II in Translationa

  2026-05-29

  This article provides translational researchers with a mechanistic and strategic perspective on deploying (-)-Blebbistatin, a selective non-muscle myosin II inhibitor, for advanced studies of cytoskeletal dynamics and cardiac physiology. Integrating foundational insights, protocol guidance, and a critical review of emerging multimodal technologies, we articulate how selective actin-myosin interaction inhibition—anchored by APExBIO's (-)-Blebbistatin—enables nuanced exploration and modulation of mechanobiological processes underlying development, disease, and therapeutic innovation.

• Comparative Antibacterial Potency of Cefoperazone and New β-

  2026-05-29

  This article reviews a pivotal study comparing N-formimidoyl thienamycin (MK0787) with recently developed β-lactam antibiotics, including cefoperazone, against resistant clinical isolates. The findings provide critical insight into the relative efficacy, bactericidal action, and β-lactamase stability among broad-spectrum agents, informing the design of robust in vitro antimicrobial assays.

• 2X Taq PCR Master Mix: Streamlined PCR for Genotyping & TA C

  2026-05-28

  The 2X Taq PCR Master Mix (with dye) from APExBIO accelerates routine and advanced molecular workflows by integrating robust DNA amplification with direct gel loading and optimal TA cloning compatibility. Explore real-world use cases, protocol enhancements, and troubleshooting strategies that make it a cornerstone PCR reagent for genotyping, cloning, and microbial ecology research.

• NSC23766 trihydrochloride: Reliable Rac1 GTPase Inhibition i

  2026-05-28

  This article addresses real-world laboratory challenges in cell viability and cancer research, demonstrating how NSC23766 trihydrochloride (SKU A1952) offers reproducible and data-driven solutions. Explore evidence-backed scenarios, protocol guidance, and vendor comparison, all tailored to maximize workflow reliability with NSC23766 trihydrochloride.

• Elobixibat Hydrate Improves Metabolic Parameters in T2DM Con

  2026-05-27

  A recent single-arm pilot study demonstrates that elobixibat hydrate, a selective ileal bile acid transporter inhibitor, not only alleviates chronic idiopathic constipation but also significantly improves glycemic control and lipid profiles in patients with type 2 diabetes mellitus (T2DM). These findings highlight elobixibat's dual therapeutic role in metabolic and gastrointestinal research and underscore its translational relevance.

• Biotin Azide in Cancer Signaling: Bridging Cholesterol and W

  2026-05-27

  Explore how Biotin Azide enables high-specificity biotin labeling in advanced cancer signaling research. This article uniquely examines its role in dissecting cholesterol–Wnt interactions and offers expert guidance for complex molecular applications.

• Mitoxantrone HCl: DNA Topoisomerase II Inhibitor in Advanced

  2026-05-26

  Mitoxantrone HCl sets a new benchmark for DNA topoisomerase II inhibitor workflows by bridging DNA damage, apoptosis induction in stem cells, and novel nuclear receptor targeting. This article delivers actionable protocols, troubleshooting insights, and comparative advantages for researchers pursuing leukemia, multiple sclerosis, and cancer resistance modeling.

• 25-Hydroxycholesterol Drives Immunosuppressive Macrophage Me

  2026-05-26

  Xiao et al. (2024) uncover how 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages drives immunosuppressive functions via lysosomal signaling and metabolic reprogramming. Targeting the CH25H-25HC axis rewires macrophage activity and synergizes with anti-PD-1 therapy, revealing a novel immunometabolic checkpoint with translational implications for cancer research.

• LGK-974: A Precision PORCN Inhibitor for Wnt Pathway Studies

  2026-05-25

  LGK-974 stands out as a potent, highly specific PORCN inhibitor, enabling robust inhibition of Wnt signaling in both in vitro and in vivo models. Its nanomolar potency and translational relevance empower advanced workflows for dissecting Wnt-driven cancer mechanisms, especially in pancreatic models with RNF43 mutations.

451 records 16/31 page Previous Next First page 上5页 1617181920 下5页 Last page